T‐DM1 operates through several mechanisms, such as the targeted delivery of DM1 to HER2+ BC cells, trastuzumab‐mediated suppression of HER2 signaling, prevention of HER2 extracellular domain shedding, and activation of ADCC [568]. This evidence concerns the gene ERBB2 and breast cancer.